Department of Pharmacology, College of Medicine, Chungnam National University
Cell signaling in metabolic syndrome and cancer
We study where cell signaling goes wrong in sarcopenia, metabolic syndrome and cancer energy metabolism, and we work toward drug candidates that correct those pathways.
- PHF20Chromatin-reading protein
- YY1Transcription factor
- PGC-1αMaster regulator of mitochondrial biogenesis
- TFAM · COX IVMitochondrial DNA maintenance and respiration
- Muscle functionWhen this pathway weakens, sarcopenia can follow
Research areas
Muscle and mitochondria
How PHF20–YY1 controls mitochondrial biogenesis genes, and why muscle is lost when this pathway fails.
Targeted protein degradation
Finding and testing sarcopenia drug candidates with targeted protein degradation (TPD), in connection with Mitos Therapeutics Inc.
Cancer energy metabolism and drug resistance
Drug resistance in ovarian cancer and glioblastoma, studied through cell signaling and lysosomal biology.
Insulin signaling and metabolic syndrome
From insulin and PI3K/PKB (AKT) signaling to metabolic syndrome and metabolic liver disease.
Join us
Motivated students and postdoctoral fellows are welcome to join our projects in biomedical science in Daejeon, South Korea.